Medication info
Olmesartan Medoxomil and S-Amlodipine Tablets 2.5/20 mg

Olmesartan Medoxomil and S-Amlodipine Tablets 2.5/20 mg

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›20mg / 1 tabletS-Amlodipine Besylate 2.5 Hydrate›3.74mg / 1 tablet
Manufacturer / importer
Dongkook Pharmaceutical Co., Ltd.
Appearance
White round film-coated tablet
Packaging
30 tablets, 300 tablets
Approval status
Active

MFDS item code 201600301 · Approved 2016.01.18 · Insurance code 653403500

Summary

Main use
Treatment of essential hypertension not controlled by monotherapy
Who takes it
Adults · Children
Adult dose
Take 1 tablet once daily with water, regardless of meals. It is recommended to take this medicine at the same time each day, if possible (e.g., in the morning). Before administering this medicine, it is recommended that the dose of each individual component (S-amlodipine (amlodipine) or olmesartan medoxomil) be adjusted. However, if blood pressure is not adequately controlled with monotherapy using the individual components, switching directly to this medicine may be considered. The maximum dose of this medicine is 5/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of 2 weeks or more, taking the patient's blood pressure response into account. The recommended doses are as follows. - 2.5/20 milligrams: For patients whose blood pressure is not adequately controlled with monotherapy using S-amlodipine 2.5 milligrams (amlodipine 5 milligrams) or olmesartan medoxomil 20 milligrams. - 2.5/40 milligrams: For patients whose blood pressure is not adequately controlled with 2.5/20 milligrams. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 2.5/40 milligrams. ○ Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild or moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ○ Patients with reduced effective circulating blood volume: In patients who may have reduced effective circulating blood volume (Intravascular volume depletion) (e.g., patients taking diuretics, especially those with renal impairment), it is recommended to initiate treatment at a low dose with adequate monitoring of their condition. ○ Patients with hepatic impairment: Use with caution in patients with mild or moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive medicines and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Patients who should not receive this medicine under Precautions for Use.) ○ Elderly patients: In general, treatment should be initiated at a low dose. When adjusting the dose, the patient's renal or cardiac function and comorbidities should be considered. Blood pressure should be monitored closely and more frequently in elderly patients.
Child dose
The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Ingredients

Manufacturer
Dongkook Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled by monotherapy

  • Essential hypertension
View approved original text

S-Amlodipine (Amlodipine) or Olmesartan Medoxomil is used to effectively lower blood pressure in patients with essential hypertension. These medications work by dilating blood vessels to control blood pressure and are prescribed when blood pressure control is difficult with monotherapy. This helps to prevent complications such as heart disease and stroke, improving overall health by stabilizing the patient's blood pressure.

How to take

Adult dose

Take 1 tablet once daily with water, regardless of meals. It is recommended to take this medicine at the same time each day, if possible (e.g., in the morning). Before administering this medicine, it is recommended that the dose of each individual component (S-amlodipine (amlodipine) or olmesartan medoxomil) be adjusted. However, if blood pressure is not adequately controlled with monotherapy using the individual components, switching directly to this medicine may be considered. The maximum dose of this medicine is 5/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of 2 weeks or more, taking the patient's blood pressure response into account. The recommended doses are as follows. - 2.5/20 milligrams: For patients whose blood pressure is not adequately controlled with monotherapy using S-amlodipine 2.5 milligrams (amlodipine 5 milligrams) or olmesartan medoxomil 20 milligrams. - 2.5/40 milligrams: For patients whose blood pressure is not adequately controlled with 2.5/20 milligrams. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 2.5/40 milligrams. ○ Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild or moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ○ Patients with reduced effective circulating blood volume: In patients who may have reduced effective circulating blood volume (Intravascular volume depletion) (e.g., patients taking diuretics, especially those with renal impairment), it is recommended to initiate treatment at a low dose with adequate monitoring of their condition. ○ Patients with hepatic impairment: Use with caution in patients with mild or moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive medicines and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Patients who should not receive this medicine under Precautions for Use.) ○ Elderly patients: In general, treatment should be initiated at a low dose. When adjusting the dose, the patient's renal or cardiac function and comorbidities should be considered. Blood pressure should be monitored closely and more frequently in elderly patients.

Child dose

The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Precautions

This medication can cause severe harm to the fetus and newborn if taken during pregnancy, especially in the second and third trimesters, so it must be discontinued immediately upon confirmation of pregnancy. Individuals with allergies to this drug's active ingredients or similar components, pregnant or nursing women, patients with severe liver or kidney diseases, and patients with certain heart diseases should not take this medication. Patients with hypotension due to insufficient fluid or salt may experience initial hypotensive symptoms during the start of this medication, so they should begin taking it under careful observation. This medication may cause rare acute hypotension due to vasodilation, so patients with vascular stenosis should be particularly cautious. Patients with heart failure or obstructive coronary artery disease may see an exacerbation of cardiac symptoms when taking this drug, hence it should be used cautiously. Patients with impaired kidney function may see further deterioration in kidney function while on this medication, requiring regular kidney function tests. Patients with reduced liver function also need to be cautious while taking this medication, and dosage adjustments may be necessary. This medication can cause various adverse reactions, commonly including dizziness, headache, hypotension, edema, indigestion, and others. There may be interactions with other medications, so it is essential to inform the doctor or pharmacist about any other medications being taken. Taking this medication during pregnancy can lead to serious issues for the fetus, so alternative medications should be considered if planning to conceive or already pregnant. If breastfeeding, there is a possibility that this medication may be transmitted through breast milk, so it is advisable to stop breastfeeding or the medication. Safety and effectiveness for patients under 18 years have not been established, so it is not recommended. Elderly patients may have increased drug concentrations in their body due to reduced kidney and liver function, so it is necessary to start at a low dose and adjust it carefully. Overdose can result in hypotension and cardiac dysfunction, requiring immediate medical attention.

Side effects

Drug hypersensitivity, hyperkalemia, decreased libido, dizziness, headache, orthostatic hypotension, drowsiness, paresthesia, reduced sensation, syncope, vertigo, palpitations, rapid pulse, hypotension, orthostatic hypotension, dyspnea, cough, nausea, vomiting, dyspepsia, diarrhea, constipation, dry mouth, abdominal pain, rash, urticaria, muscle tension, limb pain, back pain, frequency of urination, erectile dysfunction, peripheral edema, edema, dependent edema, fatigue, asthenia, facial swelling, decreased serum potassium, increased serum creatinine, increased serum uric acid, increased gamma-glutamyltransferase, decreased hemoglobin and hematocrit, back pain, bronchitis, increased creatine phosphokinase, hematuria, hyperglycemia, hypertriglyceridemia, influenza-like symptoms, pharyngitis, rhinitis, sinusitis, asthenia, angioedema, chronic malabsorption syndrome-like intestinal disease, intestinal vascular edema, rhabdomyolysis, acute kidney failure, rising serum creatinine, hair loss, itching, urticaria, autoimmune hepatitis, flushing, fatigue, edema, palpitations, dizziness, headache, drowsiness, abdominal pain, nausea, gynecomastia, jaundice, elevated liver enzymes, leukopenia, thrombocytopenia, toxic epidermal necrolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air or moisture from entering. Additionally, it should be kept away from excessively hot or cold areas, ideally at room temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

White round film-coated tablet

Package unit

30 tablets, 300 tablets

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.